Journal article
G. Vilahur, M. Aržanauskaitė, P. Sutelman, S. Ben-Aicha, M. Gutierrez, L. Casaní, O. Fjellstrom, L. Carlsson, A. Hidalgo, L. Badimón
2020
2020
Semantic Scholar
DOI
Cite
Cite
APA
Click to copy
Vilahur, G., Aržanauskaitė, M., Sutelman, P., Ben-Aicha, S., Gutierrez, M., Casaní, L., … Badimón, L. (2020). Administration of a soluble ADPase, AZD3366, on top of ticagrelor confers additional cardioprotective benefits to that of ticagrelor alone.
Chicago/Turabian
Click to copy
Vilahur, G., M. Aržanauskaitė, P. Sutelman, S. Ben-Aicha, M. Gutierrez, L. Casaní, O. Fjellstrom, L. Carlsson, A. Hidalgo, and L. Badimón. “Administration of a Soluble ADPase, AZD3366, on Top of Ticagrelor Confers Additional Cardioprotective Benefits to That of Ticagrelor Alone” (2020).
MLA
Click to copy
Vilahur, G., et al. Administration of a Soluble ADPase, AZD3366, on Top of Ticagrelor Confers Additional Cardioprotective Benefits to That of Ticagrelor Alone. 2020.
BibTeX Click to copy
@article{g2020a,
title = {Administration of a soluble ADPase, AZD3366, on top of ticagrelor confers additional cardioprotective benefits to that of ticagrelor alone},
year = {2020},
author = {Vilahur, G. and Aržanauskaitė, M. and Sutelman, P. and Ben-Aicha, S. and Gutierrez, M. and Casaní, L. and Fjellstrom, O. and Carlsson, L. and Hidalgo, A. and Badimón, L.}
}
Abstract
Preclinical and pilot human studies suggest platelet-independent cardioprotective effects of ticagrelor most likely due to its ability to block cellular uptake of adenosine. Adenosine is a potent endogenous protective molecule, concentrations of which locally rise as a response to ischemia because of the breakdown of extracellular ATP by an endothelial ADPase (apyrase, CD39) to AMP that is subsequently converted to adenosine by CD73.
In the present study we used cardiac magnetic resonance (CMR) imaging in a pig model of myocardial infarction (MI) to examine whether administration of a recombinant soluble form of ADPase, AZD3366 (APT102), confers additional benefits to that of ticagrelor alone in terms of reduced infarct size and improved heart function.
Pigs (n=20) were administered an oral loading dose of ticagrelor (180mg) and 2h later subjected to MI induction (1.5h closed-chest LAD coronary balloon occlusion). Prior to reperfusion, pigs were randomized to intravenously receive 1) vehicle (n=5); 2) 1mg/kg AZD3366 (n=5); or 3) 3mg/kg AZD3366 (n=5). After reperfusion all pigs were administered ticagrelor (90mg/bid) for 42 days. A non-treated control-MI group (n=5) was run for comparative purposes. Serial-CMR imaging was performed at baseline and 3 and 42 days post-MI for global and regional structural and functional assessments. Light transmittance aggregometry (LTA; challenged by 5, 10 and 20μM ADP) and ear bleeding time were monitored throughout the study.
Ticagrelor significantly reduced edema formation (29.8±1.9 vs. 13.1±0.9%LV) and limited infarct size (17.7±1.5 vs. 8.2±1.2%LV) at 3 days post-MI as compared to control-MI pigs (p<0.05), an effect that persisted up to 42 days. Infusion of 1mg/kg AZD3366 showed a clear signal towards further prevention of myocardial damage that reached significance at doses of 3mg/kg (additional reduction of 35% and 52% in edema and infarct size, respectively, as compared to pigs treated with ticagrelor alone; p<0.05). Left ventricular ejection fraction was higher in all ticagrelor-treated pigs at 3 and 42 days post-MI vs. control (p<0.05). Yet, regional analysis of the jeopardized myocardium revealed that pigs administered 3mg/kg AZD3366 on top of ticagrelor presented minimal dysfunctional segmental contraction as compared to the mild hypokinetic and akinetic disturbances observed in ticagrelor-alone and control-MI pigs (χ2 p<0.05 vs. all). Ticagrelor inhibited ADP-induced platelet aggregation by 30% and addition of AZD3366 acutely abolished (90% inhibition) LTA at all tested ADP doses, an effect remaining significant up to 3 days post-infusion. Ear bleeding time was not affected by AZD3366.
Infusion of a soluble recombinant ADPase (AZD3366) on top of ticagrelor leads to a greater cardioprotection as compared to ticagrelor alone. Co-administration of both drugs in AMI patients undergoing revascularization deserves to be investigated.
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Ministerio de Ciencia, Innovaciόn y Universidades / Instituto de Salud Carlos III
